Modeling the Cancer Stem Cell Hypothesis

C. Calmelet; A. Prokop; J. Mensah; L. J. McCawley; P. S. Crooke

Mathematical Modelling of Natural Phenomena (2010)

  • Volume: 5, Issue: 3, page 40-62
  • ISSN: 0973-5348

Abstract

top
Solid tumors and hematological cancers contain small population of tumor cells that are believed to play a critical role in the development and progression of the disease. These cells, named Cancer Stem Cells (CSCs), have been found in leukemia, myeloma, breast, prostate, pancreas, colon, brain and lung cancers. It is also thought that CSCs drive the metastatic spread of cancer. The CSC compartment features a specific and phenotypically defined cell population characterized with self-renewal (through mutations), quiescence or slow cycling, overexpression of anti-apoptotic proteins, multidrug resistance and impaired differentiation. CSCs show resistance to a number of conventional therapies, and it is believed that this explains why it is difficult to completely eradicate the disease and why recurrence is an ever-present threat. A hierarchical phenomenological model is proposed based on eight compartments following the stem cell lineage at the normal and cancer cell levels. As an empirical test, the tumor grading and progression, typically collected in the pathologic lab, is used to correlate the outcome of this model with the tumor development stages. In addition, the model is able to quantitatively account for the temporal development of the population of observed cell types. Two types of therapeutic treatment models are considered, with dose-density chemotherapy (a pulsatile scenario) as well as continuous, metronomic delivery. The drug hit is considered at the stem cell progenitor and early differentiated specialized cell levels for both normal and cancer cells, while the quiescent stem cell and fully differentiated compartments are considered favorable outcome for cancer treatment. Circulating progenitors are neglected in this analysis. The model provides a number of experimentally testable predictions. The relative importance of the cell kill and survival is demonstrated through a deterministic parametric study. The significance of the stem cell compartment is underlined based on this simulation study. This predictive mathematical model for cancer stem cell hypothesis is used to understand tumor responses to chemotherapeutic agents and judge the efficacy.

How to cite

top

Calmelet, C., et al. "Modeling the Cancer Stem Cell Hypothesis." Mathematical Modelling of Natural Phenomena 5.3 (2010): 40-62. <http://eudml.org/doc/197698>.

@article{Calmelet2010,
abstract = {Solid tumors and hematological cancers contain small population of tumor cells that are believed to play a critical role in the development and progression of the disease. These cells, named Cancer Stem Cells (CSCs), have been found in leukemia, myeloma, breast, prostate, pancreas, colon, brain and lung cancers. It is also thought that CSCs drive the metastatic spread of cancer. The CSC compartment features a specific and phenotypically defined cell population characterized with self-renewal (through mutations), quiescence or slow cycling, overexpression of anti-apoptotic proteins, multidrug resistance and impaired differentiation. CSCs show resistance to a number of conventional therapies, and it is believed that this explains why it is difficult to completely eradicate the disease and why recurrence is an ever-present threat. A hierarchical phenomenological model is proposed based on eight compartments following the stem cell lineage at the normal and cancer cell levels. As an empirical test, the tumor grading and progression, typically collected in the pathologic lab, is used to correlate the outcome of this model with the tumor development stages. In addition, the model is able to quantitatively account for the temporal development of the population of observed cell types. Two types of therapeutic treatment models are considered, with dose-density chemotherapy (a pulsatile scenario) as well as continuous, metronomic delivery. The drug hit is considered at the stem cell progenitor and early differentiated specialized cell levels for both normal and cancer cells, while the quiescent stem cell and fully differentiated compartments are considered favorable outcome for cancer treatment. Circulating progenitors are neglected in this analysis. The model provides a number of experimentally testable predictions. The relative importance of the cell kill and survival is demonstrated through a deterministic parametric study. The significance of the stem cell compartment is underlined based on this simulation study. This predictive mathematical model for cancer stem cell hypothesis is used to understand tumor responses to chemotherapeutic agents and judge the efficacy.},
author = {Calmelet, C., Prokop, A., Mensah, J., McCawley, L. J., Crooke, P. S.},
journal = {Mathematical Modelling of Natural Phenomena},
keywords = {Stem cell; mathematical model; hypothesis; cancer therapy; stem cell},
language = {eng},
month = {4},
number = {3},
pages = {40-62},
publisher = {EDP Sciences},
title = {Modeling the Cancer Stem Cell Hypothesis},
url = {http://eudml.org/doc/197698},
volume = {5},
year = {2010},
}

TY - JOUR
AU - Calmelet, C.
AU - Prokop, A.
AU - Mensah, J.
AU - McCawley, L. J.
AU - Crooke, P. S.
TI - Modeling the Cancer Stem Cell Hypothesis
JO - Mathematical Modelling of Natural Phenomena
DA - 2010/4//
PB - EDP Sciences
VL - 5
IS - 3
SP - 40
EP - 62
AB - Solid tumors and hematological cancers contain small population of tumor cells that are believed to play a critical role in the development and progression of the disease. These cells, named Cancer Stem Cells (CSCs), have been found in leukemia, myeloma, breast, prostate, pancreas, colon, brain and lung cancers. It is also thought that CSCs drive the metastatic spread of cancer. The CSC compartment features a specific and phenotypically defined cell population characterized with self-renewal (through mutations), quiescence or slow cycling, overexpression of anti-apoptotic proteins, multidrug resistance and impaired differentiation. CSCs show resistance to a number of conventional therapies, and it is believed that this explains why it is difficult to completely eradicate the disease and why recurrence is an ever-present threat. A hierarchical phenomenological model is proposed based on eight compartments following the stem cell lineage at the normal and cancer cell levels. As an empirical test, the tumor grading and progression, typically collected in the pathologic lab, is used to correlate the outcome of this model with the tumor development stages. In addition, the model is able to quantitatively account for the temporal development of the population of observed cell types. Two types of therapeutic treatment models are considered, with dose-density chemotherapy (a pulsatile scenario) as well as continuous, metronomic delivery. The drug hit is considered at the stem cell progenitor and early differentiated specialized cell levels for both normal and cancer cells, while the quiescent stem cell and fully differentiated compartments are considered favorable outcome for cancer treatment. Circulating progenitors are neglected in this analysis. The model provides a number of experimentally testable predictions. The relative importance of the cell kill and survival is demonstrated through a deterministic parametric study. The significance of the stem cell compartment is underlined based on this simulation study. This predictive mathematical model for cancer stem cell hypothesis is used to understand tumor responses to chemotherapeutic agents and judge the efficacy.
LA - eng
KW - Stem cell; mathematical model; hypothesis; cancer therapy; stem cell
UR - http://eudml.org/doc/197698
ER -

References

top
  1. R.W. Cho, X. Wang X, M. Diehn, K. Shedden, GY Ghen, G Sherlock, A Gurney, J Lewicki MF Clarke. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells, 26 (2008), No. 2, 364-71. 
  2. J. Demongeot, M. Kaufman R. Thomas. Positive feedback circuits and memory. C. R. Acad. Sci. III.323 (2000), No. 1, 69-79. 
  3. D. Dingli, A. Traulsen J. Pacheco. Stochastics Dynamics of Hematopoietic Tumor Stem Cells. Cell Cycle6 (2007), No. 4, 461-466. 
  4. V.S. Donnenberg, R.J. Landreneau A.D. Donnenberg. Tumorigenic stem and progenitor cells: implications for the therapeutic index of anti-cancer agents. Journal Control Release, 122 (2007), No. 3, 385-91. 
  5. H. Enderling, M. A. Chaplain, A.R. Andersona, J. S. Vaidyab. A mathematical model of breast cancer development, local treatment and recurrence. Journal of Theoretical Biology, 246 (2007) No. 2, 245-259.  
  6. D. Fang, T. K. Nguyen, K. Leishear, R. Finko, A. N. Kulp, S. Hotz, P. A. Van Belle, X. Xu, D. E. Elder, M. Herlyn. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res.65, (2005), No. 20, 9328-37.  
  7. M. Freeman J.B. Gurdon. Regulatory principles of developmental signaling. Annu. Rev. Cell. Dev. Biol.18 (2002), 515-39. 
  8. R. Ganguly I.K. Puri. Mathematical model for the cancer stem cell hypothesis. Cell Prolif.39 (2006), No. 1, 3-14. 
  9. R. Ganguly I.K. Puri. Mathematical model for chemotherapeutic drug efficacy in arresting tumour growth based on the cancer stem cell hypothesis. Cell Prolif.40 (2007), No. 3, 338-54. 
  10. R.P. Hill. Identifying cancer stem cells in solid tumors: case not proven. Cancer Res.66 (2006), No. 4, 1891-5. 
  11. M.D. Johnston, C.M. Edwards, W.F. Bodmer, P.K. Maini S.J. Chapman. Mathematical modeling of cell population dynamics in the colonic crypt and in colorectal cancer. Proc. Natl. Acad. Sci.104 (2007), No. 10, 4008-13. 
  12. E.A. King-Smith A. Morley. Computer simulation of granulopoiesis: normal and impaired granulopoiesis. Blood.36 (1970), No. 2, 254-62. 
  13. B. Laquente, F. ViŰals J.R. GermĹ. Metronomic chemotherapy: an antiangiogenic scheduling. Clin. Transl. Oncol.9 (2007), No. 2, 93-8. 
  14. M. Leszczyniecka, T. Roberts, P. Dent, S. Grant, P.B. Fisher. Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther.90 (2001) No. 2-3, 105-56.  
  15. I. Malanchi J. Huelsken. Cancer Stem cells: never Wnt away from the niche. Current Opinion in Oncology21 (2008), 41-46. 
  16. J.A. Marchal, F. RodrŠguez-Serrano, R. Madeddu, H. Boulaiz, A. Martinez-Amat, E. Carrillo, O. Caba, J.C. Prados, C. Velez, C. Melguizo, A. Montella A. Aranega. Differentiation: an encouraging approach to anticancer therapy. J. Anat. Embryol.111 (2006), No. 1, 45-64. 
  17. F. Michor, T.P. Hughes, Y. Iwasa, S. Branford, N. P. Shah, C. L. Sawyers, M. A. Nowack. Dynamics of Chronic Myeloid Leukaemia., Nature435 (2005) 1267-1270.  
  18. J.A. Nilsson J.L. Cleveland. Myc pathways provoking cell suicide and cancer. Oncogene.22 (2003), No. 56, 9007-21. 
  19. A.B. Pardee. Regulatory molecular biology. Cell Cycle.5 (2006), No. 8, 846-52. 
  20. A.B. Pardee. Tumor progression–targets for differential therapy. J. Cell Physiol.209 (2006), No. 3, 589-91. 
  21. I. Roeder, M. Horn, I. Glauche, A. Hochlaus, M. C. Mueller M. Loeffler. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nature Medicine12 (2006), 1181-1184. 
  22. T. Schatton, N.Y. Frank, M.H Frank. Identification and targeting of cancer stem cells. Bioessays31 (2009) No. 10, 1038-49.  
  23. R. Thomas. Laws for the dynamics of regulatory networks. Int. J. Dev. Biol.42 (1998), No. 3, 479-85. 
  24. M.J. Tindall. Modelling the cell cycle and cell movement in multicellular tumour spheroids. Bull. Math. Biol.69 (2007), No. 4, 1147-65. 
  25. W. C. Lo, C. S. Chou, K. K. Gokoffski, F. Y. Wan, A.D. Lander, A. L. Calof Q. Nie. Feedback regulation in multistage cell lineages. Math. Biosci. Eng.6 (2009), No. 1, 59-82. 

NotesEmbed ?

top

You must be logged in to post comments.

To embed these notes on your page include the following JavaScript code on your page where you want the notes to appear.

Only the controls for the widget will be shown in your chosen language. Notes will be shown in their authored language.

Tells the widget how many notes to show per page. You can cycle through additional notes using the next and previous controls.

    
                

                
Note: Best practice suggests putting the JavaScript code just before the closing </body> tag.